Veradermics Raises $295M in Upsized IPO, Exceeding Expectations
Event summary
- Veradermics closed its upsized IPO on February 5, 2026, raising $294.8M from 17.3M shares sold at $17.00 per share.
- Underwriters fully exercised their option to purchase an additional 2.3M shares.
- Shares began trading on the NYSE under the ticker symbol 'MANE' on February 4, 2026.
- The offering was led by Jefferies, Leerink Partners, Citigroup, and Cantor as joint book-running managers.
The big picture
Veradermics' successful upsized IPO reflects strong investor appetite for late-stage dermatology therapeutics, particularly in the aesthetic space. The $295M raise positions the company to advance its lead candidate, VDPHL01, while expanding its portfolio in a market increasingly focused on non-invasive and oral treatments. The deal underscores the growing interest in dermatology as a high-growth sector within biopharma.
What we're watching
- Clinical Progress
- How the $295M capital infusion will accelerate Veradermics' lead program, VDPHL01, an oral treatment for pattern hair loss.
- Market Performance
- Whether Veradermics can sustain momentum post-IPO, given the competitive landscape in aesthetic dermatology.
- Portfolio Expansion
- The pace at which Veradermics will develop its pipeline beyond VDPHL01, including potential medical dermatology candidates.
Our editorial coverage:
Related topics